10
2
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T14881 |
CB1 antagonist 2
AM4113 |
Cannabinoid Receptor | GPCR/G Protein |
CB1 antagonist 2 (AM4113) 是一种 caimabinoid 1 拮抗剂,在体内抑制 CB1 的IC50值为 25.5 nM。 | |||
T41350 |
6-Bromopravadoline
WIN 54461 |
Cannabinoid Receptor | GPCR/G Protein |
6-Bromopravadoline (WIN 54461) (WIN 54461) 是CB1受体的拮抗剂。6-Bromopravadoline 作为 [3H]Win 55212-2 的结合抑制剂 (IC50=515 nM),反映了其与大麻素受体结合。 | |||
T8511 |
TM38837
|
Cannabinoid Receptor | GPCR/G Protein |
TM38837 是外周选择性大麻素受体1型受体拮抗剂。它减少精神病副作用的倾向。它对大脑的渗透率有限,以降低或防止 CNS 不良反应,并保留潜在的抗肥胖作用。 | |||
T68500 | AZD-2207 | ||
AZD-2207 is a cannabinoid receptor CB1 antagonist and highly lipophilic compound for the treatment of type 2 diabetes mellitus and obesity. | |||
T68515 | AZD-1175 | ||
AZD-1175 is a cannabinoid receptor CB1 antagonist and highly lipophilic compound for the treatment of type 2 diabetes and obesity. | |||
T78674 |
Isopropyl dodec-11-enylfluorophosphonate
IDEFP |
FAAH | Metabolism; Neuroscience |
Isopropyl dodec-11-enylfluorophosphonate (IDEFP) 为有机磷酯类化合物,能抑制中枢大麻素受体 (cannabinoid receptor) (CB1) 并具有相似的效力抑制FAAH(IC50s = 2 nM)。 | |||
T21914 |
(S)-SLV 319
|
||
Ibipinabant (SLV319) 是一种有效,选择性和具有口服活性的大麻素 CB1 受体 (cannabinoid CB1 receptor) 的拮抗剂,Ki 值为 7.8 nM。Ibipinabant 对 CB1 的选择性超过 CB2 (Ki=7943 nM) 的 1000 倍以上。Ibipinabant 可用于肥胖和糖尿病的研究。 | |||
T38199 |
(±)-WIN 55,212 (mesylate)
|
||
(±)-WIN 55,212-2 is a potent aminoalkylindole cannabinoid (CB) receptor agonist with a Ki value of 62.3 and 3.3 nM for human recombinant central cannabinoid (CB1) and peripheral cannabinoid (CB2) receptors, respectively. In contrast, the enantiomer (-)-WIN 55,212-3 acts a partial inverse agonist at CB1 (pIC50 = 5.5) and as a competitive neutral antagonist of CB2, reversing the inverse agonism evoked by SR 144528 (pEC50 = 5.3). (+)-WIN 55,212 (mesylate) is a mixture of the two enantiomers, (+)-WI... | |||
T23099 |
O-2050
|
Others | Others |
O-2050 是一种高亲和力的大麻素CB1受体拮抗剂,Ki 为 2.5 nM。O-2050 抑制大麻素 CB2受体,Ki 为 0.2 nM。O-2050 减少了小鼠的食物摄入量,并且引起小鼠运动。 | |||
T35468 |
(±)19(20)-EDP Ethanolamide
|
||
(±)19(20)-EDP ethanolamide is an ω-3 endocannabinoid epoxide and cannabinoid (CB) receptor agonist (EC50s = 108 and 280 nM for CB1 and CB2, respectively). It is produced through direct epoxygenation of docosahexaenoyl ethanolamide by cytochrome P450 (CYP) epoxygenases. (±)19(20)-EDP ethanolamide (25 μM) reduces the viability of 143B metastatic osteosarcoma cells. It decreases the production of IL-6 and increases the production of IL-10 when used at concentrations ranging from 2.5 to 10 μM in BV-... |
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
TN1465 |
Cannabigerol
|
NOS; 5-HT Receptor; ROS | GPCR/G Protein; Immunology/Inflammation; Neuroscience |
Cannabigerol 是一种植物大麻素,是一种高亲和力 α2-肾上腺素能受体激动剂、中度亲和力 5-HT1A 受体拮抗剂和低亲和力 CB1/CB2受体拮抗剂。它可降低眼压,有潜力治疗青光眼。 | |||
TN5131 |
Tetrahydrocannabivarin
THCV,delta9-Tetrahydrocannabivarin,CRM,Tetrahydrocannavarin |
Cannabinoid Receptor | GPCR/G Protein |
Tetrahydrocannabivarin (CRM) 是 cannabinoid type 1 receptor 的中性拮抗剂,对 2 型糖尿病有潜在治疗价值。 |